Before PSSW, both the FXa inhibitor and dabigatran groups were older; had higher CHA2DS2-VASc and HAS-BLED scores; and had several comorbidities, including hypertension, dyslipidemia, and stroke, compared with the warfarin group (ASMD >0.1) (Table). This evidence concerns the gene F10 and Hypertension.